BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

manilatimes.net · 2026-10-22

BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer This will be the first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugateMAINZ, Germany, October 22, 2026 - BioNTech SE (Nasdaq: BNTX, 'BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. ('Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate ('ADC”) sacituzumab govitecan (Trodelvy®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer ('TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb ('BMS”).

TickrTrends take: Gilead's involvement in this collaborative Phase 3 trial with BioNTech represents potential upside from combination therapy development, though such clinical advances typically require years to translate into revenue. Given TickrTrends' current overvalued assessment of Gilead in the Healthcare sector, investors focused on valuation should monitor whether this partnership creates meaningful near-term financial impact or remains a longer-term clinical milestone that does not justify current pricing. The trial's progress will be worth tracking against Gilead's ability to justify its present valuation through revenue realization rather than clinical potential alone.

Read the full story at manilatimes.net →